Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ORCHESTRATE: LDR with Gem-based Doublets and SBRT for Pancreatic Cancer
NCT02416609Unknown
- Sponsor
- Azienda Ospedaliera Universitaria Policlinico
- Start
- Jan 2014
- Primary completion
- Nov 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of gemcitabine in pancreatic adenocarcinoma (PDAC), sponsored by Azienda Ospedaliera Universitaria Policlinico. Primary endpoint: Progression-free survival at 1 year. Status: unknown.
02
Drugs
gemcitabine
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT02416609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02416609.